SCM
FHTX icon

Suvretta Capital Management’s Foghorn Therapeutics FHTX Stock Holding History

Suvretta Capital Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-84,000
Closed -$1.17M – 102
2021
Q3 		$1.17M Hold
84,000
– – 0.02% 97
2021
Q2 		$896K Hold
84,000
– – 0.01% 116
2021
Q1 		$1.11M Sell
84,000
-174,700
-68% -$2.86M 0.02% 97
2020
Q4 		$5.24M Buy
+258,700
New +$4.96M 0.07% 75

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Suvretta Capital Management's FHTX Position: Q4 2021 in Review

Suvretta Capital Management sold out of Foghorn Therapeutics (FHTX) in Q4 2021, closing a stake of 84,000 shares — an estimated $1.17M sold.

Suvretta Capital Management first reported a position in FHTX in Q4 2020 and held it in 4 quarters. The position peaked at $5.24M in Q4 2020. 60 funds tracked by Wall St. Rank hold FHTX as of Q4 2021.

  • Suvretta Capital Management reported no remaining Foghorn Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Suvretta Capital Management sold 84,000 Foghorn Therapeutics shares in Q4 2021, an estimated $1.17M.
  • Suvretta Capital Management first reported a position in Foghorn Therapeutics in Q4 2020 and held it in 4 quarters.
  • Suvretta Capital Management's Foghorn Therapeutics position peaked at $5.24M in Q4 2020.
  • 60 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q4 2021.

Based on Suvretta Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.